Quest Diagnostics Inc DGX posted a better-than-expected Q2 FY22 adjusted EPS of $2.36, though down 25.8% Y/Y, beating the consensus of $2.20.
Sales came in at $2.45 billion, a decline of 3.8% Y/Y, higher than the Wall Street estimate of $2.34 billion.
COVID-19 testing revenues fell 30.5% to $355 million, while Base business revenues improved 2.9% to $2.10 billion.
“In Q2, our base business revenues grew year over year while we increased our share of COVID-19 molecular testing thanks largely to our expanded retail relationships,” said Jim Davis, CEO-elect.
Adjusted operating margin compressed to 17.7% from 22.9% a year ago.
Outlook: Quest Diagnostics expects FY22 sales of $9.50 billion – $9.75 billion (prior view $9.2 billion – $9.5 billion), compared to the consensus of $9.42 billion.
The company tightened its Base revenue guidance to $8.35 billion – $8.45 billion (prior guidance of $8.35 billion – $8.50 billion).
The company anticipates higher COVID-19 testing revenues of $1.15 billion – $1.30 billion (prior forecast of $0.85 billion – $1.0 billion).
The company forecasts adjusted EPS of $9.55 – $9.95 compared to the prior guidance of $9.00-$9.50, versus the consensus of $9.33.
Price Action: DGX shares are up 0.12% at $135.00 during the premarket session on the last check Thursday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
